Key facts
- Foundation Fighting Blindness Retinal Degeneration Fund filed SCHEDULE 13D/A for Opus Genetics, Inc. Common Stock, $0.0001 par value per share (IRD).
- Disclosed ownership: 4.7%.
- Date of event: 18 May 2026.
Foundation Fighting Blindness Retinal Degeneration Fund - 18 May 2026 SCHEDULE 13D/A Report for Opus Genetics, Inc. Common Stock, $0.0001 par value per share (IRD)
- Filing Manager
- Foundation Fighting Blindness Retinal Degeneration Fund
- Reporting Manager
- Foundation Fighting Blindness Retinal Degeneration Fund
- Symbol
- IRD
- Shares outstanding
- 81,377,060 shares
- Disclosed Ownership
- 3,792,171 shares
- Ownership
- 4.7%
- Form type
- SCHEDULE 13D/A
- Filing time
- 20 May 2026, 19:53:32 UTC
- Date of event
- 18 May 2026
- Previous filing
- 11 Dec 2025
- SEC
- View on sec.gov
Key filing fact
Foundation Fighting Blindness Retinal Degeneration Fund disclosed 4.7% ownership in Opus Genetics, Inc. Common Stock, $0.0001 par value per share (IRD) on 18 May 2026.
Change
- Previous schedule filing date: 11 Dec 2025.
- Current filing was accepted on 20 May 2026, 19:53.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (2)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Foundation Fighting Blindness Retinal Degeneration Fund | 4.7% | 3,792,171 | 0 | 3,792,171 | /s/ Russell Kelley | Russell Kelley, Managing Director | 0002042266 |
| Foundation Fighting Blindness, Inc. | 4.7% | 3,792,171 | 0 | 3,792,171 | /s/ Jason Menzo | Jason Menzo, Chief Executive Officer | 0002042532 |
CIK / CUSIP context first